论文部分内容阅读
目的观察贝伐单抗联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌患者的临床疗效及安全性。方法入选64例中晚期肝癌患者,随机分成试验组33例和对照组31例,对照组给予奥沙利铂90~140 mg,5-氟尿嘧啶1.0 g及超液化碘油10~30 m L进行TACE治疗;试验组在TACE治疗介入前,经导管动脉灌注贝伐单抗4~6 mg·kg~(-1),疗程均为6周。评价2组患者术后3,6个月的临床疗效和临床收益率;术前、术后3个月的血清甲胎蛋白及生存质量卡式评分;术后6,12个月的生存率及不良反应。结果试验组术后3,6个月的临床收益率分别为81.8%,75.8%,高于对照组的51.6%,41.9%(P<0.05)。试验组术后血清甲胎蛋白水平为(402.21±11.42)μg·L~(-1),显著低于对照组的(439.45±12.03)μg·L~(-1)(P<0.05)。试验组12个月生存率为84.4%,显著高于对照组的51.7%(P<0.05)。结论贝伐单抗联合TACE能有效提高中晚期肝癌的临床疗效,且不增加不良反应的发生率。
Objective To observe the clinical efficacy and safety of bevacizumab in combination with transcatheter arterial chemoembolization (TACE) in the treatment of patients with primary liver cancer. Methods Sixty-four patients with advanced hepatocellular carcinoma (HCC) were enrolled and randomly divided into experimental group (n = 33) and control group (n = 31). The control group was treated with oxaliplatin 90-140 mg, 5- fluorouracil 1.0 g and hyperlipemic lipiodol 10-30 m The experimental group was given bevacizumab 4 ~ 6 mg · kg ~ (-1) via TAC before intervention of TACE. The course of treatment was 6 weeks. The clinical efficacy and clinical rate of return after 3 and 6 months of operation in both groups were evaluated. The score of serum alpha-fetoprotein and quality of life on preoperative and postoperative 3 months, the survival rate at 6 and 12 months after operation, Adverse reactions. Results The 3 and 6 months after operation, the clinical rates of return were 81.8% and 75.8% respectively, which were higher than those of the control group (51.6% and 41.9%, P <0.05). The level of serum alpha-fetoprotein in the experimental group was (402.21 ± 11.42) μg · L -1, which was significantly lower than that in the control group (439.45 ± 12.03 μg · L -1) (P <0.05). The 12-month survival rate of the experimental group was 84.4%, significantly higher than that of the control group (51.7%, P <0.05). Conclusion Bevacizumab combined with TACE can effectively improve the clinical efficacy of advanced liver cancer without increasing the incidence of adverse reactions.